Pramiconazole: Difference between revisions
Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation ( |
No edit summary |
||
Line 1: | Line 1: | ||
{{ |
{{drugbox |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = 4SYH0R661F |
|||
| verifiedrevid = 366890982 |
| verifiedrevid = 366890982 |
||
| IUPAC_name = 1-{4-[4-(4-{[(2''R'',4''S'')-2-(2,4-difluorophenyl)-2-(1''H''-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-3-isopropylimidazolidin-2-one |
| IUPAC_name = 1-{4-[4-(4-{[(2''R'',4''S'')-2-(2,4-difluorophenyl)-2-(1''H''-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-3-isopropylimidazolidin-2-one |
Revision as of 23:58, 30 June 2011
{{drugbox | UNII_Ref = | UNII = 4SYH0R661F | verifiedrevid = 366890982 | IUPAC_name = 1-{4-[4-(4-{[(2R,4S)-2-(2,4-difluorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-3-isopropylimidazolidin-2-one | image = Pramiconazole.png | width = | image2 = | width2 = | imagename = | drug_name = | CAS_number = | CAS_supplemental = | ATC_prefix = none | ATC_suffix = | ATC_supplemental = | PubChem = 11411233 | DrugBank = | chemical_formula = | C=35 | H=39 | F=2 | N=7 | O=4 | molecular_weight = 659.725 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = }}
Pramiconazole is a triazole antifungal undergoing research for the treatment of acute skin and mucosal fungal infections.
It is developed by Barrier Therapeutics.